Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Novel mechanistic insights towards the repositioning of alogliptin in Parkinson's disease
Marwa M. Safar, Noha F. Abdelkader, Eman Ramadan, et al.
Life Sciences (2021) Vol. 287, pp. 120132-120132
Closed Access | Times Cited: 24

Showing 24 citing articles:

Neuroprotective effect of liraglutide in an experimental mouse model of multiple sclerosis: role of AMPK/SIRT1 signaling and NLRP3 inflammasome
Reham A. Ammar, Ahmed F. Mohamed, Mohamed M. Kamal, et al.
Inflammopharmacology (2022) Vol. 30, Iss. 3, pp. 919-934
Open Access | Times Cited: 47
Empagliflozin alleviates endoplasmic reticulum stress and augments autophagy in rotenone-induced Parkinson's disease in rats: Targeting the GRP78/PERK/eIF2α/CHOP pathway and miR-211-5p
Tarek K. Motawi, Rawan H. Al-Kady, Sahar M. Abdelraouf, et al.
Chemico-Biological Interactions (2022) Vol. 362, pp. 110002-110002
Closed Access | Times Cited: 44
DPP-4 inhibitors and type 2 diabetes mellitus in Parkinson’s disease: a mutual relationship
Mohammed Alrouji, Hayder M. Al‐kuraishy, Ali K. Albuhadily, et al.
Pharmacological Reports (2023) Vol. 75, Iss. 4, pp. 923-936
Closed Access | Times Cited: 21
DPP-4 inhibitors sitagliptin and PF-00734,200 mitigate dopaminergic neurodegeneration, neuroinflammation and behavioral impairment in the rat 6-OHDA model of Parkinson’s disease
Seong‐Jin Yu, Yun Wang, Hui Shen, et al.
GeroScience (2024) Vol. 46, Iss. 5, pp. 4349-4371
Open Access | Times Cited: 7
Dapagliflozin as an autophagic enhancer via LKB1/AMPK/SIRT1 pathway in ovariectomized/d-galactose Alzheimer’s rat model
Weam W. Ibrahim, Ahmed S. Kamel, Ahmed Wahid, et al.
Inflammopharmacology (2022) Vol. 30, Iss. 6, pp. 2505-2520
Open Access | Times Cited: 33
Incretin-based drugs as potential therapy for neurodegenerative diseases: current status and perspectives
Federica Ferrari, Antonio Moretti, R. F. Villa
Pharmacology & Therapeutics (2022) Vol. 239, pp. 108277-108277
Closed Access | Times Cited: 32
Association between Parkinson’s Disease and Diabetes Mellitus: From Epidemiology, Pathophysiology and Prevention to Treatment
Haiyang Yu, Tong Sun, He Xin, et al.
Aging and Disease (2022) Vol. 13, Iss. 6, pp. 1591-1591
Open Access | Times Cited: 30
Mechanistic insights toward progress in alogliptin beyond glycemic control: translational perspective
Faraha Ahmed, Syed Sufian Ahmad, Mohammad Mumtaz Alam, et al.
Beni-Suef University Journal of Basic and Applied Sciences (2025) Vol. 14, Iss. 1
Open Access
HMGB1 in nervous system diseases: A common biomarker and potential therapeutic target
Di Mao, Zheng Yuan, Fenfen Xu, et al.
Frontiers in Neurology (2022) Vol. 13
Open Access | Times Cited: 25
Exendin-4 and linagliptin attenuate neuroinflammation in a mouse model of Parkinson′s disease
Haiyang Yu, Tong Sun, Zhen Wang, et al.
Neural Regeneration Research (2022)
Open Access | Times Cited: 24
Cilostazol novel neuroprotective mechanism against rotenone-induced Parkinson's disease in rats: Correlation between Nrf2 and HMGB1/TLR4/PI3K/Akt/mTOR signaling
Rehab M. El‐Sayed, Ahmed M. Abdelaziz, Hala F. Zaki, et al.
International Immunopharmacology (2023) Vol. 117, pp. 109986-109986
Closed Access | Times Cited: 11
Potential neuroprotective and autophagy-enhancing effects of alogliptin on lithium/pilocarpine-induced seizures in rats: Targeting the AMPK/SIRT1/Nrf2 axis
Sarah S El-Sayed, Shimaa O. Ali, Weam W. Ibrahim
Life Sciences (2024) Vol. 352, pp. 122917-122917
Closed Access | Times Cited: 3
Boosting amygdaloid GABAergic and neurotrophic machinery via dapagliflozin-enhanced LKB1/AMPK signaling in anxious demented rats
Ahmed S. Kamel, Ahmed Wahid, Noha F. Abdelkader, et al.
Life Sciences (2022) Vol. 310, pp. 121002-121002
Closed Access | Times Cited: 15
Neuroprotective effect of secukinumab against rotenone induced Parkinson's disease in rat model: Involvement of IL-17, HMGB-1/TLR4 axis and BDNF/TrKB cascade
Yara T. Mohamed, Abeer Salama, Mostafa A. Rabie, et al.
International Immunopharmacology (2022) Vol. 114, pp. 109571-109571
Closed Access | Times Cited: 15
Dipeptidyl peptidase 4(DPP4) inhibitors stride up the management of Parkinson's disease
Maanvi, Shilpa Kumari, Rahul Deshmukh
European Journal of Pharmacology (2022) Vol. 939, pp. 175426-175426
Closed Access | Times Cited: 14
GLP-1/GIP Agonist as an Intriguing and Ultimate Remedy for CombatingAlzheimer’s Disease through its Supporting DPP4 Inhibitors: A Review
Mohammad Abubakar, Lokesh Nama, Mohammad Arif Ansari, et al.
Current Topics in Medicinal Chemistry (2024) Vol. 24, Iss. 19, pp. 1635-1664
Closed Access | Times Cited: 2
Promising biomarkers and therapeutic targets for the management of Parkinson's disease: recent advancements and contemporary research
Mohammad Ahmed Khan, Nafis Haider, Tanveer Singh, et al.
Metabolic Brain Disease (2023) Vol. 38, Iss. 3, pp. 873-919
Closed Access | Times Cited: 7
Anti-Inflammatory Effects of Dipeptidyl Peptidase-4 Inhibitors and Their Therapeutic Application for Parkinson's Disease
Yeojin Bang, Soung-Hee Moon, Sumin Lee, et al.
Drug Targets and Therapeutics (2024) Vol. 3, Iss. 1, pp. 83-93
Open Access | Times Cited: 1
Acteoside alleviates blood–brain barrier damage induced by ischemic stroke through inhibiting microglia HMGB1/TLR4/NLRP3 signaling
Yucheng Liao, Junping Hu, Chao Guo, et al.
Biochemical Pharmacology (2023) Vol. 220, pp. 115968-115968
Closed Access | Times Cited: 3
Novel and experimental therapeutics for the management of motor and non-motor Parkinsonian symptoms
Inam Ullah, Xin Wang, Hongyu Li
Neurological Sciences (2024) Vol. 45, Iss. 7, pp. 2979-2995
Closed Access
Sitagliptin elevates plasma and CSF incretin levels following oral administration to nonhuman primates: relevance for neurodegenerative disorders
Yazhou Li, Kelli L. Vaughan, Yun Wang, et al.
GeroScience (2024) Vol. 46, Iss. 5, pp. 4397-4414
Open Access
Impact of alogliptin on Lipopolysaccharide-Induced Experimental Parkinson’s disease: Unrevealing Neurochemical and Histopathological alterations in rodents.
Maanvi Dhureja, Rahul Deshmukh
European Journal of Pharmacology (2024) Vol. 975, pp. 176635-176635
Closed Access
Incretin Mimetics Restore the ER-Mitochondrial Axis and Switch Cell Fate Towards Survival in LUHMES Dopaminergic-Like Neurons: Implications for Novel Therapeutic Strategies in Parkinson’s Disease
Theodora Panagaki, Elisa B. Randi, Csaba Szabó, et al.
Journal of Parkinson s Disease (2023) Vol. 13, Iss. 7, pp. 1149-1174
Open Access
Exenatide Improves the Luteinizing Hormone Pulse in Obese Polycystic Ovary Syndrome Rats by Upregulating Sirtuin-1 in the Hypothalamus
Bo Lv, Chuan Xing, Han Zhao, et al.
SSRN Electronic Journal (2022)
Closed Access
Page 1

Scroll to top